查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1734875

2032 年紫杉醇注射市場預測：按產品類型、劑型、劑量、通路、適應症、最終用戶和地區進行的全球分析

Paclitaxel Injection Market Forecasts to 2032 - Global Analysis By Product Type (Conventional Paclitaxel Injection and Albumin-bound Paclitaxel Injection), Formulation, Dosage Strength, Distribution Channel, Indication, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球紫杉醇注射市場預計在 2025 年達到 70.1 億美元，到 2032 年將達到 166 億美元，預測期內的複合年成長率為 13.2%。

紫杉醇注射是一種化療藥物，用於治療多種癌症，包括乳癌、卵巢和肺癌。紫杉醇透過抑制細胞分裂和破壞微管功能來發揮作用，阻止癌細胞增殖。紫杉醇靜脈注射注射給藥，通常與其他抗癌藥物合併使用以增強療效。其製劑中含有有助於藥物溶解的溶劑，因此需要謹慎給藥以控制潛在的副作用。作為一種廣泛使用的化療藥物，紫杉醇在腫瘤治療方案中發揮重要作用。

根據美國醫療保險和醫療補助服務中心 (CMS) 的數據，美國醫療保健成本將從 2022 年到 2023 年成長 7.5%，高於 2021 年到 2022 年的 4.6% 的增幅。

癌症發生率增加

全球癌症發生率的上升迫使醫療保健提供者採用更有效的治療方案，從而加強了紫杉醇在腫瘤學領域的角色。癌症研究和早期檢測方法的進步進一步擴大了治療機會，並促進了化療藥物的使用。此外，人們對癌症管理的認知不斷提高以及醫療基礎設施的不斷發展也推動了市場的成長。

嚴重的副作用

紫杉醇注射液相關的嚴重副作用，例如神經病變、免疫抑制和過敏反應，對其廣泛應用構成了挑戰。接受化療的患者通常會因藥物的細胞毒性而感到不適，需要額外的支持性治療。對藥物耐受性和長期療效的擔憂阻礙了市場的成長，因為控制副作用需要謹慎用藥。

創新藥物輸送系統

奈米顆粒製劑和標靶治療等新技術可增強藥物吸收，並最大程度降低全身性毒性。脂質體遞送和聚合物載體可最佳化藥物釋放控制，延長療效並減少副作用。隨著製藥公司對先進藥物遞送技術的投入，改進紫杉醇製劑的開發有望改變癌症治療策略。

嚴格的核准流程和品質標準

紫杉醇注射必須經過嚴格的品質和安全測試，這延長了產品核可的時間。國際監管差異要求進行廣泛的臨床試驗，這使得新藥的商業化更加複雜。此外，嚴格的上市後監管和合規性監控進一步增加了製藥商的營運成本，影響了投資決策和市場准入。

COVID-19的影響：

疫情擾亂了供應鏈和癌症治療的時間表，暫時影響了紫杉醇注射的供應。由於醫院就診受限以及新冠治療資源分配不足，許多癌症治療面臨延誤。遠距醫療監控和個人化治療方法的研究進展支撐了癌症藥物的持續需求，確保了市場的持續擴張。

預計傳統紫杉醇注射劑市場在預測期內將佔據最大佔有率

鑑於其在化療中的既定作用，預計常規紫杉醇注射將在預測期內佔據最大的市場佔有率。紫杉醇廣泛應用於腫瘤治療方案，確保了其穩定的需求，因為醫療保健提供者將繼續依賴其成熟的製劑進行癌症管理。常規紫杉醇注射因其在治療多種癌症方面的有效性而受到青睞，這鞏固了其在市場上的主導地位。

預計在預測期內，脂質體紫杉醇部分將以最高的複合年成長率成長。

脂質體紫杉醇領域預計將在預測期內實現最高成長率，這得益於其能夠降低全身毒性並提高藥物傳輸效率。封裝技術提高了癌細胞靶向的精準度，從而改善了患者預後並減少了副作用。脂質體製劑可延長循環時間並控制藥物釋放，使其成為傳統化療的頗具吸引力的替代方案。

比最大的地區

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於該地區癌症發病率的上升和醫療基礎設施的進步。中國和印度等國家正在積極投資癌症治療，擴大其製藥產能，並開發具有成本效益的化療方案，這進一步刺激了亞太地區市場的發展。

複合年成長率最高的地區：

由於藥物研究的突破、藥物投資的不斷成長以及先進治療方法的加速應用，預計北美將在預測期內實現最高的複合年成長率。對癌症藥物開發的日益關注，加上正在進行的臨床試驗和FDA對新製劑的核准，正在推動市場擴張。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球紫杉醇注射劑市場（依產品類型）

  • 常規紫杉醇注射液
  • 白蛋白結合型紫杉醇注射液

6. 全球紫杉醇注射劑市場（按劑型）

  • 聚合物膠束配方
  • 奈米白蛋白紫杉醇
  • 脂質體紫杉醇
  • 其他準備

7. 全球紫杉醇注射劑市場（按劑量）

  • 30mg/5ml
  • 100mg/16.7ml
  • 260 mg/43.4 ml
  • 其他劑量強度

8. 全球紫杉醇注射劑市場（按通路）

  • 醫院藥房
  • 零售藥局
  • 直銷

9. 全球紫杉醇注射劑市場（按適應症）

  • 愛滋病相關卡波西氏肉瘤
  • 乳癌
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌
  • 肺癌/胃癌
  • 其他適應症

第 10 章全球紫杉醇注射液市場（依最終用戶）

  • 癌症治療中心
  • 門診手術中心
  • 專科診所
  • 其他最終用戶

第 11 章全球紫杉醇注射劑市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Celgene Corporation
  • Sagent Pharmaceuticals
  • Fresenius Kabi Oncology Ltd
  • Abbott Laboratories
  • Bristol Myers Squibb
  • Luye Pharma Group
  • Pfizer
  • Teva Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries Ltd
  • Sanofi
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company
  • Cipla Ltd
  • Mylan NV
  • Aurobindo Pharma
  • NOVASEP
Product Code: SMRC29512

According to Stratistics MRC, the Global Paclitaxel Injection Market is accounted for $7.01 billion in 2025 and is expected to reach $16.6 billion by 2032 growing at a CAGR of 13.2% during the forecast period. Paclitaxel injection is a chemotherapy medication used to treat various cancers, including breast, ovarian, and lung cancer. It works by inhibiting cell division, disrupting microtubule function, and preventing cancer cells from proliferating. Administered intravenously, paclitaxel is often combined with other anticancer agents to enhance therapeutic efficacy. Its formulation includes solvents that aid drug solubility, requiring careful administration to manage potential side effects. As a widely utilized chemotherapy drug, paclitaxel plays a crucial role in oncology treatment protocols.

According to the Centers for Medicare and Medicaid Services (CMS), health spending in the U.S. increased by 7.5% from 2022 to 2023, faster than the 4.6% increase from 2021 to 2022.

Market Dynamics:

Driver:

Increasing incidence of cancers

Increasing cancer prevalence worldwide is pushing healthcare providers to adopt more effective therapeutic solutions, reinforcing the role of paclitaxel in oncology. Advancements in cancer research and early detection methods are further expanding treatment accessibility, encouraging higher use of chemotherapy drugs. Additionally, growing awareness regarding cancer management and evolving healthcare infrastructure are accelerating market growth.

Restraint:

Severe side effects

Severe side effects associated with paclitaxel injections, such as neuropathy, immune suppression, and allergic reactions, present challenges to widespread adoption. Patients undergoing chemotherapy often experience discomfort due to the drug's cytotoxic nature, requiring additional supportive treatments. Managing adverse effects demands careful dosing, leading to concerns about tolerability and long-term patient outcomes impeding the market growth.

Opportunity:

Innovative drug delivery systems

Emerging techniques, such as nanoparticle-based formulations and targeted therapies, enhance drug absorption and minimize systemic toxicity. Liposomal delivery and polymer-based carriers are optimizing controlled drug release, ensuring prolonged efficacy with fewer adverse reactions. As pharmaceutical companies invest in advanced drug delivery technologies, the development of improved paclitaxel formulations is expected to transform cancer treatment strategies.

Threat:

Stringent approval processes and quality standards

Paclitaxel injection formulations must undergo rigorous testing to meet quality and safety requirements, prolonging product approval timelines. Varying international regulations demand extensive clinical trials, adding to the complexity of commercializing new drug variations. Additionally, strict post-market surveillance and compliance monitoring further increase operational costs for pharmaceutical manufacturers, influencing investment decisions and market accessibility.

Covid-19 Impact:

The pandemic disrupted supply chains and oncology treatment schedules temporarily affecting paclitaxel injection availability. Many cancer treatments faced delays due to restricted hospital access and resource allocation toward COVID-19 care. Research advancements in remote healthcare monitoring and personalized treatment approaches are supporting sustained demand for oncology medications, ensuring continued market expansion.

The conventional paclitaxel injection segment is expected to be the largest during the forecast period

The conventional paclitaxel injection segment is expected to account for the largest market share during the forecast period due to its established role in chemotherapy treatments. Its widespread use in oncology protocols ensures consistent demand, as healthcare providers continue to rely on proven formulations for cancer management. Conventional paclitaxel injections are preferred for their effectiveness in treating multiple cancer types, reinforcing their dominance in the market.

The liposomal paclitaxel segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the liposomal paclitaxel segment is predicted to witness the highest growth rate driven by its ability to reduce systemic toxicity and enhance drug delivery efficiency. Encapsulation technologies improve precision in targeting cancer cells, leading to better patient outcomes with fewer side effects. Liposomal formulations offer prolonged circulation and controlled drug release, making them an attractive alternative to traditional chemotherapy methods.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share fueled by increasing cancer prevalence and advancements in regional healthcare infrastructure. Countries such as China and India are actively investing in oncology treatment accessibility, expanding pharmaceutical production capacities, and developing cost-effective chemotherapy solutions is further driving market growth in Asia-Pacific.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to the breakthroughs in drug research, growing pharmaceutical investments, and accelerated adoption of advanced treatment methods. Strong emphasis on oncology drug development, coupled with ongoing clinical trials and FDA approvals for novel formulations, is reinforcing market expansion.

Key players in the market

Some of the key players in Paclitaxel Injection Market include Celgene Corporation, Sagent Pharmaceuticals, Fresenius Kabi Oncology Ltd, Abbott Laboratories, Bristol Myers Squibb, Luye Pharma Group, Pfizer, Teva Pharmaceuticals, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Sanofi, Merck & Co., Inc., Takeda Pharmaceutical Company, Cipla Ltd, Mylan N.V., Aurobindo Pharma and NOVASEP.

Key Developments:

In May 2025, Sun Pharma launched a corporate brand campaign in India, reinforcing its position as the country's leading pharmaceutical company. The campaign aims to enhance brand visibility and connect with a broader audience.

In May 2025, Celgene Corporation, now a part of Bristol Myers Squibb, continues to operate under the BMS umbrella. While specific press releases under the Celgene name are limited post-acquisition, the company remains integral to BMS's oncology portfolio.

In April 2025, Luye Pharma Group announced the U.S. launch of ERZOFRI(R) (paliperidone palmitate) extended-release injectable suspension. The product is indicated for the treatment of adults with schizophrenia and schizoaffective disorder.

Product Types Covered:

  • Conventional Paclitaxel Injection
  • Albumin-bound Paclitaxel Injection

Formulations Covered:

  • Polymeric Micelle Formulations
  • Nab-Paclitaxel
  • Liposomal Paclitaxel
  • Other Formulations

Dosage Strengths Covered:

  • 30 mg/5 ml
  • 100 mg/16.7 ml
  • 260 mg/43.4 ml
  • Other Dosage Strengths

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Direct Sales

Indications Covered:

  • AIDS-related Kaposi's Sarcoma
  • Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Lung/Stomach Cancer
  • Other Indications

End Users Covered:

  • Cancer Treatment Centers
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Paclitaxel Injection Market, By Product Type

  • 5.1 Introduction
  • 5.2 Conventional Paclitaxel Injection
  • 5.3 Albumin-bound Paclitaxel Injection

6 Global Paclitaxel Injection Market, By Formulation

  • 6.1 Introduction
  • 6.2 Polymeric Micelle Formulations
  • 6.3 Nab-Paclitaxel
  • 6.4 Liposomal Paclitaxel
  • 6.5 Other Formulations

7 Global Paclitaxel Injection Market, By Dosage Strength

  • 7.1 Introduction
  • 7.2 30 mg/5 ml
  • 7.3 100 mg/16.7 ml
  • 7.4 260 mg/43.4 ml
  • 7.5 Other Dosage Strengths

8 Global Paclitaxel Injection Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Direct Sales

9 Global Paclitaxel Injection Market, By Indication

  • 9.1 Introduction
  • 9.2 AIDS-related Kaposi's Sarcoma
  • 9.3 Breast Cancer
  • 9.4 Ovarian Cancer
  • 9.5 Pancreatic Cancer
  • 9.6 Prostate Cancer
  • 9.7 Lung/Stomach Cancer
  • 9.8 Other Indications

10 Global Paclitaxel Injection Market, By End User

  • 10.1 Introduction
  • 10.2 Cancer Treatment Centers
  • 10.3 Ambulatory Surgical Centers
  • 10.4 Specialty Clinics
  • 10.5 Other End Users

11 Global Paclitaxel Injection Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Celgene Corporation
  • 13.2 Sagent Pharmaceuticals
  • 13.3 Fresenius Kabi Oncology Ltd
  • 13.4 Abbott Laboratories
  • 13.5 Bristol Myers Squibb
  • 13.6 Luye Pharma Group
  • 13.7 Pfizer
  • 13.8 Teva Pharmaceuticals
  • 13.9 Dr. Reddy's Laboratories
  • 13.10 Sun Pharmaceutical Industries Ltd
  • 13.11 Sanofi
  • 13.12 Merck & Co., Inc.
  • 13.13 Takeda Pharmaceutical Company
  • 13.14 Cipla Ltd
  • 13.15 Mylan N.V.
  • 13.16 Aurobindo Pharma
  • 13.17 NOVASEP

List of Tables

  • Table 1 Global Paclitaxel Injection Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Paclitaxel Injection Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Paclitaxel Injection Market Outlook, By Conventional Paclitaxel Injection (2024-2032) ($MN)
  • Table 4 Global Paclitaxel Injection Market Outlook, By Albumin-bound Paclitaxel Injection (2024-2032) ($MN)
  • Table 5 Global Paclitaxel Injection Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 6 Global Paclitaxel Injection Market Outlook, By Polymeric Micelle Formulations (2024-2032) ($MN)
  • Table 7 Global Paclitaxel Injection Market Outlook, By Nab-Paclitaxel (2024-2032) ($MN)
  • Table 8 Global Paclitaxel Injection Market Outlook, By Liposomal Paclitaxel (2024-2032) ($MN)
  • Table 9 Global Paclitaxel Injection Market Outlook, By Other Formulations (2024-2032) ($MN)
  • Table 10 Global Paclitaxel Injection Market Outlook, By Dosage Strength (2024-2032) ($MN)
  • Table 11 Global Paclitaxel Injection Market Outlook, By 30 mg/5 ml (2024-2032) ($MN)
  • Table 12 Global Paclitaxel Injection Market Outlook, By 100 mg/16.7 ml (2024-2032) ($MN)
  • Table 13 Global Paclitaxel Injection Market Outlook, By 260 mg/43.4 ml (2024-2032) ($MN)
  • Table 14 Global Paclitaxel Injection Market Outlook, By Other Dosage Strengths (2024-2032) ($MN)
  • Table 15 Global Paclitaxel Injection Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 16 Global Paclitaxel Injection Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 17 Global Paclitaxel Injection Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 18 Global Paclitaxel Injection Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 19 Global Paclitaxel Injection Market Outlook, By Indication (2024-2032) ($MN)
  • Table 20 Global Paclitaxel Injection Market Outlook, By AIDS-related Kaposi's Sarcoma (2024-2032) ($MN)
  • Table 21 Global Paclitaxel Injection Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 22 Global Paclitaxel Injection Market Outlook, By Ovarian Cancer (2024-2032) ($MN)
  • Table 23 Global Paclitaxel Injection Market Outlook, By Pancreatic Cancer (2024-2032) ($MN)
  • Table 24 Global Paclitaxel Injection Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 25 Global Paclitaxel Injection Market Outlook, By Lung/Stomach Cancer (2024-2032) ($MN)
  • Table 26 Global Paclitaxel Injection Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 27 Global Paclitaxel Injection Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Paclitaxel Injection Market Outlook, By Cancer Treatment Centers (2024-2032) ($MN)
  • Table 29 Global Paclitaxel Injection Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 30 Global Paclitaxel Injection Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 31 Global Paclitaxel Injection Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.